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Background: National Health Service stop smoking services (NHS SSS) in the UK offer cost- effective smoking
cessation services. Despite high abstinence rates after acute cessation treatment, the majority of clients have
relapsed by one year. Several interventions have been identified, from trial data, as effective in preventing relapse
to smoking. This study investigated uptake, feasibility and acceptability of offering nicotine replacement therapy
(NRT) as a relapse prevention intervention (RPI) in NHS SSS.
Methods: Eligible smokers who had successfully completed acute cessation treatment using NRT at Nottingham
City NHS SSS between April 2010 and January 2011 were offered the RPI and the rate of uptake was monitored.
Consenting individuals completed a baseline questionnaire, providing demographic and smoking behaviour data.
The RPI consisted of using NRT for a further 12 weeks after initial cessation-orientated treatment had ended. At a
six-month review, self-reported smoking status was assessed via telephone. Anonymised demographic data on NHS
SSS users who did not agree to participate in the study were retrieved from NHS SSS records and used to
determine the presence of any socio-demographic differences between individuals who agreed to participate in
the study and those who did not. Semi-structured telephone interviews were conducted with a selection of
participants; these were audio-recorded, transcribed and analysed to identify participants’ views on the RPI.
Results: Of 493 stop smoking service clients who were assessed, 260 were eligible for and offered the RPI and 115
(44%, CI 38%- 50%) accepted. Individuals who accepted NRT were significantly more likely to be older (p < 0.001)
and to pay for their prescriptions (p < 0.001). Quitters who had never worked or were unemployed were
significantly less likely to accept the offer of relapse prevention compared to those in routine and manual
occupations (55% reduction in odds, p = 0.026).
Interview findings revealed that clients who accepted extended NRT felt the longer duration of pharmacological
and psychological support were both valuable in helping them to remain abstinent.
Conclusion: In routine smoking cessation service care, it is feasible to offer clients extended courses of NRT as a
RPI. The RPI was acceptable to them as almost half of the eligible clients offered this treatment accepted it.
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Smoking is a cause of significant preventable morbidity and
mortality [1]; consequently, reduction in smoking preva-
lence is a priority for governments and health care systems
across the world. The World Health Organisation’s Frame-
work Convention on Tobacco Control (FCTC), the world’s
first public health treaty, recommends a comprehensive
strategy that participating countries can adopt to reduce to-
bacco use including advertising bans, the use of taxation
and price increases, smoke-free policies, health promotion
and mass media tobacco control campaigns, and cessation
support. Many countries have smoking cessation services
which offer advice and support for smokers to encourage
them to quit successfully.
The United Kingdom has implemented a comprehen-
sive tobacco control strategy over recent years [2]
including a national network of smoking cessation ser-
vices, largely provided by the National Health Service
(NHS); these services are referred to as the NHS stop
smoking services (NHS SSS) (Table 1). NHS SSS com-
monly provide eight-12 weeks smoking cessation sup-
port incorporating pharmacological and psychological
therapies to clients who are motivated to quit. Nicotine
replacement therapy (NRT), buproprion and varenicline
have been proven to be cost- effective with 15% of cli-
ents smoke-free at one year [3]. Recent data show 48%
of NHS SSS clients have stopped smoking four weeks
after setting a quit date [4], however, the majority (85%)
have relapsed to smoking by one year, reflecting theTable 1 Characteristics of stop smoking services
Background Established in 1999 in the mo
Rolled out across the UK from
Represent a unique national i
Service provision Service provision framework i
smokers [2]
Usually involves regular meet
structured withdrawal-oriente
Smoking cessation medicatio
programme involving an initi
quit attempt is continuing [3]
If a smokers’ attempt to quit
when considering whether a
smoking again [4]
Training Smoking cessation staff come
They are trained in the provis
This training is currently being
for Smoking Cessation and Tr
Targets For the first ten years, targets
services who set a quit date a
Smoking cessation services ar
population, in line with best p
and Clinical Excellence prograaddictive nature of cigarette smoking [5]. High relapse
rates are common in other similar services offered
elsewhere [6]. Effective relapse prevention interventions
(RPIs) offered at the end of current treatment could
therefore increase long term success rates. Systematic re-
views have concluded that RPIs in the form of extended
use of NRT, buproprion or varenicline are probably ef-
fective when used to prevent relapse amongst smokers
who have recently become abstinent [7,8] and economic
modelling suggests that this use of extended treatment is
likely to be highly cost effective [9]. However, most trial
data are from countries without the cessation infrastruc-
ture seen in the UK and hence their applicability to rou-
tine health care settings such as the NHS is unclear.
There is also evidence that smokers trying to stop often
use short and incomplete courses of NRT [10,11] and
hence identifying the uptake and acceptability of longer
courses of treatment is of importance to inform both
NHS and similar services internationally. A recent study
has identified that, despite there being no evidence to
support this view, some providers of NHS SSS are
concerned that clients will not accept RPIs that involve
using medications for prolonged periods [12]. In this
study we therefore investigated the uptake, feasibility
and acceptability of offering extended courses of NRT as
a relapse prevention intervention to recently abstinent
quitters who had been helped to achieve abstinence in a
routine health care setting, NHS SSS located across the
city of Nottingham.st disadvantaged areas in England
2000
nitiative to provide support for smokers motivated to quit [1]
s based on an evidenced based approach to treating dependent
ings (one to one or in groups) with a trained adviser, using
d behavioural support combined with smoking cessation medications [1]
ns are usually offered on the basis of an abstinent-contingent treatment
al course of two to four weeks, followed by further prescriptions if the
is unsuccessful, advisers can use discretion and professional judgement
client is immediately ready to receive support to attempt to stop
from a wide variety of backgrounds
ion of treatments to help with stopping smoking
standardised in England through a newly established National Centre
aining
were set within England for the numbers of smokers attending the
nd who quit smoking four weeks after the start of treatment
e currently expected in the course of a year to treat 5% of their local
ractice recommendations contained within National Institute for Health
mme guidance for smoking cessation [3]
Number assessed as eligible and 
offered relapse prevention = 260 
Number that accepted offer of 
NRT for relapse prevention = 115
Attended first appointment and 
received a month’s supply of 
NRT= 89 
Attended second month 
appointment and received a 
month’s supply of NRT= 66
Contacted at month six - 
Self reported abstinence= 
37
Contacted at month six - Self 
reported relapse= 35
Attended third month appointment 
and received final supply of NRT= 
47
Number of quitters assessed for 
eligibility= 493 
Figure 1 Study flow chart.
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Design
Ten NHS SSS clinics were selected from clinics offering
specialist intensive smoking cessation support across
Nottingham to include a range of sociodemographic catch-
ment areas. The clinics were located within Nottingham
City at GP surgeries, Community Centres and Children’s
Centres. All clients at these settings who had completed
acute cessation treatment eight weeks after their quit dates,
and for whom self-reported abstinence was validated with
an expired air carbon monoxide (CO) measurement of
<8 ppm. were offered study enrolment by their smoking
cessation advisor.
Sample
Eligible clients were those who had used NRT for their
acute cessation treatment, were between 18 and 65 years
of age and had been regular smokers for 12 months
prior to their cessation treatment, and these were offered
RPI in the form of extended courses of NRT. Relapse
prevention treatment was not offered to those who were
pregnant or breastfeeding, individuals with known
hypersensitivity to NRT, individuals with unstable car-
diovascular disease, unstable cerebrovascular disease in-
cluding transient ishchaemic attacks, chronic generalised
skin disorders or major psychiatric disorders. These indi-
viduals were excluded on the basis of information
contained within the Nottingham New Leaf Clinical
Guidance, (April 2010) which states that clients in these
categories are “special precaution groups”. Individuals
who used other tobacco products including cigars, pipe
tobacco, snuff and chewing tobacco were also excluded.
Participants consented to receive extended NRT therapy
for up to 12 weeks, to potentially be interviewed about this
and to be followed up at six months. Those enrolled com-
pleted a baseline questionnaire, which sought their views
on using the additional NRT treatment. We also sought
permission to conduct follow up at six months for those
clients who did not wish to receive extended NRT therapy;
these participants were also given a short questionnaire
asking about reasons for declining participation.
Relapse prevention intervention
Individuals who agreed to receive an extended course of
NRT were issued with a four week supply of the same
NRT product that they had used for acute cessation and
they were asked to return in one month for a further four
weeks’ supply to be provided by a cessation adviser, con-
tingent on their continued abstinence from smoking (de-
fined as not having smoked more than five cigarettes in
the last month, with five or fewer cigarettes being defined
as lapses and an expired air carbon monoxide (CO) meas-
urement of <8 ppm). Individuals who reported that they
had smoked more than five cigarettes in the month priorto the visit, and with a CO level greater than 8 ppm were
not issued additional NRT and were withdrawn from the
study.
The following forms of NRT were available for relapse
prevention: 24 hour patch, 16 hour patch, 2 mg gum,
4 mg gum, 1 mg lozenge, 2 mg lozenge, 4 mg lozenge,
nasal spray and inhalator and 2 mg microtabs. A final
month’s NRT was supplied at a third appointment after
identical procedures had been followed. Brief counselling
support was offered and CO measured at each appoint-
ment. Additionally, at each appointment, participants
provided information on smoking status, and completed
questionnaires asking about the difficulty and acceptabil-
ity they perceived in using NRT for an extended period
NRT, and any side effects experienced.
At six months, an attempt was made to contact all
participants who had agreed to telephone follow up re-
garding self-reported smoking status with three attempts
at calling made; when this was successful, self-reported
abstinence (i.e. no cigarettes smoked over the last
month) was recorded. The stages involved in the study
are described in Figure 1.
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Anonymised demographic data on NHS SSS users who
did not agree to participate in the study and who did not
wish to be contacted at six month follow-up were re-
trieved from the NHS SSS records and used to deter-
mine the presence of any socio-demographic differences
between individuals who agreed to participate in the
study and those who did not. Data on individuals who
refused to participate but agreed to be contacted at six
months were also included. These data included age,
gender, ethnicity, payment for prescriptions and occupa-
tion. Data were retrieved between the months of July
2010 and February 2011.
Data were analysed using STATA statistical software
[13]. Summary statistics were performed to estimate the
proportion of individuals who accepted the offer of an
extended course of NRT (the primary outcome), based
on responses to the questionnaire items. Bivariate ana-
lyses using chi-squared tests and t-tests were performed
to assess any differences in age, gender, ethnicity, occu-
pation and payment for prescriptions between those
who accepted the offer of extended treatment and those
who did not.
Qualitative research
Participants who consented to be interviewed were se-
lected purposively to give a range of socio-demographic
backgrounds and were then contacted via telephone. At-
tempts were made to include individuals who were still
abstinent, individuals who had relapsed and individuals
who had experienced a lapse. Interviews took place over
the telephone from May 2010 to April 2011 at between
one and four months after they had entered the study.
Two different semi-structured interview guides were
used; one for clients who had relapsed to smoking and
another for those who were abstinent at the time of
interview. Guides asked about smoking history, experi-
ence of using NRT, the effectiveness of treatment, con-
cerns about taking treatment, consideration of other
treatments (specifically bupropion and varenicline), the
optimum way of accessing NRT for RPI and circum-
stances of any lapses to smoking. All who participated in
the interviews were offered £10 shopping vouchers.
JT (an author) conducted interviews which were digit-
ally audio-recorded and transcribed verbatim. Tran-
scripts were open coded and a thematic framework was
developed, in the context of the study aims, after consid-
eration of themes emerging from the data [14]. Tran-
scripts and the framework were then distributed to all
other researchers for review; themes were validated and
refined and then re-coded where required. Mapping was
then used to look for associations and exceptions. Quali-
tative data analysis software was not used in the analysis
Quotations in the results section are identified by sex,age and occupational status [retired, unemployed/sick,
routine and manual, intermediate]/ professional].
Ethical approval
The study was approved by the Derbyshire Research
Ethics Committee, REC reference number 09/H0401/87.
The study also received organizational approval from the
research and development department of Nottingham-
shire County Teaching PCT.
Results
Of 493 recent quitters seen in the study clinics, 260 were
eligible for the offer of relapse prevention treatment and
115 (44%, 95% confidence interval, CI 38%-50%) ac-
cepted the offer. Reasons for declining the offer of re-
lapse prevention were given as follows: satisfied with
eight weeks’ NRT (n = 66, 46%); inability to attend
monthly follow-ups (n = 29, 20%); concern about long-
term use of NRT (n = 10, 7%); and ‘other’ (n = 40, 28%).
The following explanations were given for those in the
‘other category: “taking champix”, “health problems”, “no
longer using NRT”, “special circumstances”, “taking
zyban”, and “declined without providing reasons”. The
mean age of participants was 43 years, (SD, 11.9 years),
most were White British (76%), slightly over half of the
participants were female (54%) and around two thirds
were exempt from prescription payments (64%).
Table 2 presents participants’ socio-demographic details
and Table 3 compares socio-demographic characteristics of
those accepting the offer of the RPI with those who did not.
Those who accepted NRT were significantly more likely to
be older (p < 0.001) and to pay for their NRT prescriptions
(p < 0.001). Quitters who had never worked or were un-
employed were significantly less likely to accept the offer of
relapse prevention compared to those in routine and man-
ual occupations (55% reduction in odds, p = 0.026).
Of those who agreed to use the extended courses of
NRT, 77% (n = 89) attended the one month follow-up and
were issued with a second month’s supply of NRT; 57%
(n = 66) attended the two month follow-up and were issued
with a third month supply of NRT; 41% (n = 47) attended
the three month follow-up. At each clinic visit, there
was 100% agreement between a participant’s self-reported
smoking status and CO measurements, as recorded by the
stop smoking advisor (clients are told about CO testing and
know to expect it). At the six month telephone follow up,
63% (n = 72) of participants were contacted.
Ease of usage, acceptability and side effects
Of those followed up in the first month, 98% of individuals
reported that they found it “very easy” or “easy” to use the
NRT products, this remained at 97% and 98% of individ-
uals finding NRT use “very easy” or “easy” at months two
and three respectively. Ninety seven percent of individuals
Table 2 Sociodemographics of individuals accepting and declining the RPI
Variable Individuals accepting RPI
(n = 115) (As percentage
of variable.)
Individuals declining RPI
(n = 145) (As percentage
of variable.)
Total offered RPI
(n = 260) (As percentage of variable.)
Age:
18-25 1 (0.9%) 15 (10.3%) 16 (6.2%)
26-33 11 (9.6%) 23 (15.9%) 34 (13.1%)
34-41 25 (21.7%) 40 (27.6%) 65 (25%)
42-49 30 (26.1%) 27 (18.6%) 57 (21.9%)
50-57 23 (20%) 21 (14.5%) 44 (16.9%)
58-65 25 (21.7%) 19 (13.1%) 44 (16.9%)
Gender:
female 66 (57.4%) 75 (51.7%) 141 (54.2%)
male 49 (42.6%) 70 (48.3%) 119 (45.8%)
Payment for prescriptions:
Paid 41 (35.7%) 23 (15.9%) 64 (24.6%)
Exempt 64 (55.6%) 102 (70.3%) 166 (63.9%)
Unknown 10 (8.7%) 20 (13.8%) 30 (11.5%)
Ethnicity:
White 103 (89.6%) 113 (77.9%) 216 (83%)
Other 11 (9.6%) 15 (10.3%) 26 (10%)
Not recorded 1 (0.8%) 17 (11.8%) 18 (7%)
Occupation:
Full time student 5 (4.3%) 6 (4.1%) 11 (4.2%)
Home carer 9 (7.8%) 13 (9.0%) 22 (8.4%)
Intermediate 6 (5.2%) 10 (6.8%) 16 (6.2%)
Managerial/ professional 3 (2.6%) 5 (3.4%) 8 (3.1%)
Never worked/ unemployed 19 (16.5%) 35 (24.1%) 54 (20.8%)
Retired 13 (11.3%) 4 (2.8%) 17 (6.5%)
Sick/disabled/unable to work 9 (7.8%) 13 (9.0%) 22 (8.5%)
Unable to code 1 (0.9%) 18 (12.4%) 19 (7.3%)
Unknown 3 (2.6%) 2 (1.4%) 5 (1.9%)
Routine and manual 47 (41%) 39 (27%) 86 (33.1%)
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the experience of using NRT at one month; this satisfac-
tion was maintained, with 97% and 96% of those followed
up in the second and third month stating they were
“pleased” or “very pleased” with the NRT.
A total of 27 (30%) participants reported that they expe-
rienced side effects to NRT in the first month, 14 (21%) in
the second month and 10 (21%) participants in the third
month. The most commonly reported side effects were
skin rash from the patches, indigestion and insomnia.
Abstinence at six month follow-up
Of the 115 participants who took part in the study, 37
(32%, 95% CI 24%-41%) self -reported being abstinent
at six month follow-up, 35 (30%, 95% CI 22%-39%)individuals had relapsed and 43 (37%) individuals were lost
to follow-up. Only two of the eleven non-participants who
consented to be followed up were contactable at six
month follow up and both had relapsed to smoking.
Interview findings
Nineteen interviews were performed. After 16 interviews
no new themes were identified and a further three inter-
views were conducted to confirm data saturation. Par-
ticipant demographics and relapse/ abstinence status are
outlined in Table 4.
In general, the interviewees felt that the RPI was very
helpful and they reflected on it positively. The principal
themes identified were reasons for continuing quit suc-
cess, the concept of and reasons for relapse, choice of
Table 3 Comparison of individuals who accepted and
declined the offer of relapse prevention treatment
(univariate analysis)
Variable Odds ratio 95% CI P-values
Age: 0.001
Per year 1.04 1.02-1.06
Gender: 0.363
female 1.26 0.77-2.06
male Reference group
Payment for prescriptions: 0.001
Paid 2.84 1.56-5.17
Exempt Reference group
Ethnicity: 0.604
White 1.24 0.55-2.83
Other Reference group
Occupation: 0.024
Full time student 0.69 0.20-2.44
Home carer 0.57 0.22-1.49
Intermediate 0.50 0.17-1.49
Managerial/ professional 0.50 0.11-2.22
Never worked/ unemployed 0.45 0.22-0.91
Retired 2.70 0.81-8.94
Sick/disabled/unable to work 0.57 0.22-1.49
Unable to code 0.05 0.01-0.36
Unknown 1.25 0.20-7.83
Routine and manual Reference group
Table 4 Socio-demographic breakdown of qualitative
research interviews
Number of
participants
Gender
Male 5
Female 14
Age
18-25 1
26-33 1
34-41 2
42-49 4
50-57 8
58-65 3
Smoking status at interview
Relapsed 4
Lapse(s) 1
Abstinent 14
Payment for NRT prescriptions
Exempt from prescription charges 11
Pay for prescriptions 8
Occupation
Unemployed/ sick disabled 4
Routine and Manual 7
Professional/ intermediate 3
Retired 5
Used NHS SSS during previous quit attempts. 7
Total number of previous quit attempts
None 2
1or 2 7
3 or more 10
Number of years smoking
<10 1
11-20 3
21-30 2
31-40 7
41+ 6
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ings from those themes which relate to the new RPI be-
ing evaluated are described in more detail below.
Reasons for quit success
Participants outlined several factors relating to the ex-
tended treatment that they felt had helped them re-
main abstinent.
The majority of participants perceived that the NHS
SSS advisor support was important for practical advice
and motivational support, both in the initial cessation
period and in the prolonged relapse prevention stage.
The use of a carbon monoxide detector was identified as
a deterrent to relapse but also as an indicator of physical
improvement in the initial cessation stage (Table 5).
NRT was seen as crucial to reducing cravings and
physical dependence. Interviewees had several theories
as to why prolonged therapy with NRT may have im-
proved their ability to quit and remain stopped. These
included the concept that the level of physical addiction
was related to the extent of smoking history and that
those who had been smoking for longer might need lon-
ger to be weaned off smoking. Another concept wasthat changing ingrained, habitual behaviour is a lengthy
process and the longer period of support provided a
more appropriate timeframe for this. Other interviewees
felt the extended support and treatment was a ‘back-up’
or ‘fail safe’ (Table 5). However, all participants identified
that, once a quit attempt had started, NRT alone was
not enough to maintain abstinence; self motivation, sup-
port from friends, family and formal support services
such as the NHS SSS advisors were also important.
Table 5 Quotes illustrating ‘Reasons for quit success’
Reasons for quit success To start with it was because she was going to do the breathing test. . . and there was no way
I was going to fail that. . .(F, 63, Retired)
It’s important to me (speaking to an advisor) because. . . I know someone is there that I can
talk to. . .(F, 27, Routine / Manual)
I think for me because I had been a smoker for so long. . . it was doing it over a long period
of time. I think it did me good; I took longer to wean myself down. (F, 63, Retired)
The government has given you. . .where they say. . .we are going to stop just after 12 weeks. . .
it’s too short. . .too short a time period. . .because my body has gotten used to say 29. . .39 years,
nearly 40 years of smoking. . .you can’t do that. . .stop in 12 weeks. . . (M, 56, Routine / Manual)
Yeah, I found erm, I don’t know whether it was just comfort, just to know it was there, you know
what I mean? I think if someone had just stuck a plaster on my arm. . .whether that sounds a bit
silly. . .I just felt I needed it. . . (Female, 55, Retired)
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Participants who had lapsed or relapsed to smoking often
described feelings of guilt and occasionally mentioned
feeling physically unwell after smoking. Several partici-
pants, regardless of smoking status, identified the theory
of ‘social smoking’ or having ‘just one’ as not really being
considered smoking. Reasons proffered for previous or
current failure in quit attempts were usually related to per-
sonal stress. Some individuals recognized that lack of mo-
tivation or support from friends, family or partners was
also a contributing factor, especially during previous quit
attempts conducted on their own (Table 6).
Choice of service
NHS SSS face to face clinics were the preferred format
and provider of support for relapse prevention treat-
ment; this was because they were considered convenient,
were free and the service was often considered to be bet-
ter quality than at alternative providers such as pharma-
cies and general practices. Some patients mentioned the
importance of not having to pay for prescriptions for
NRT, and this often determined their response as to
where they would like to receive medication from.
Whilst it was recognized that, for some people, face to
face appointments at NHS SSS were more difficult to at-
tend, the majority of interviewees felt that these were of
added benefit because carbon monoxide readings could
be performed and communication was easier. However,
there was some enthusiasm for support provided via
telephone amongst interviewees too (Table 7).Table 6 Quotes illustrating ‘Concept of, and reasons for, relap
Concepts and reasons for relapse So I went outside. . .realized w
(F, 52, Routine/Manual)
The last one was a month ago
I don’t really consider that as s
There was one particular incide
seriously ill and I went to care
again. . .(F, 50, Sick/ Unemploy
I think it didn’t work before be
heart into it before. (F, 39, RouConcerns about prolonged NRT use
No patient stated concerns about continuing NRT for a
longer period of time. However, being able to stop using
nicotine replacement entirely was seen as desirable as a
long-term goal.
Discussion
Main findings
To our knowledge this is the first study to attempt to
quantify the potential demand for relapse prevention
treatment within routine smoking cessation care. We
found that 44% of eligible clients who had achieved ces-
sation using NRT and NHS SSS support accepted an
offer of extended treatment with NRT; of these 41% con-
tinued using NRT for 12 weeks. These findings suggest
that there would be a reasonable demand for RPIs (at
least among those using NRT for acute cessation) if they
were to be routinely offered by NHS SSS. Overall, the
qualitative research indicated that participants were gener-
ally satisfied with the RPI that they had received, welcom-
ing both the extension of NRT supplies as well as the
continuing contact with the NHS SSS advisors and there
were few concerns about the extended use of NRT.
Strengths and limitations
The study was carried out in a selected sample of NHS
SSS in one large city and may not therefore be represen-
tative of all smoking cessation services in the UK or else-
where. Nevertheless, we selected services covering a
range of socio-demographic areas and this is borne outse’
hat I was doing. . .and got rid of it. . .and I felt guilty then for doing it. . .
and before that I was smoking 20 a day. So although I have had one
moking. . .(F, 39, Routine/ Manual)
nt where I had given up, and then my father-in-law’s step mum became
for her. And in all fairness to get me through that I started smoking
ed)
cause, I think it needed to come from me more. I don’t think I put my
tine/ Manual)
Table 7 Quotes illustrating ‘Choice of service’
Choice of service I think it should be free though. . .for everyone not just people like me on benefits
(F, 39, Routine/ Manual)
For me it was the clinic and that was it. If it wasn’t for the clinic I think I would still
be smoking. (F, 60, Routine/ Manual)
That protected time with a professional therapist. I think it’s very important to have
that protected time, even if it’s for only a few minutes, where you know it’s just
you and your mentor (F, 56, Intermediate/ Professional)
I think the (local NHS SSS) is better because. . . you get to talk to your advisor. . .if
you just go to the pharmacy there’s other people there. . .you might not get much
time because the pharmacy is busy. . .(F, 21, Unemployed)
No, I think it has to be face to face. . . and you have to blow into that carbon
monoxide indicator. . .(F, 49, Intermediate/Professional)
I don’t mind the telephone thing at all. . . I finish work at 2 o’clock it saves me from
going back out again. . .(M, 56, Routine/Manual)
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clusion criteria were based mainly on the stop smoking
service supply criteria for NRT but did result in around
half of the clients being excluded. Further research is ne-
cessary with some of the excluded groups, such as those
with psychiatric disease and for extended treatments
may be particularly important, given the high rates of
heavy dependent smoking in these groups. As such it ex-
cluded pregnant women and individuals younger than
18 years and older than 65 years and we were unable to
assess the feasibility and acceptability of NRT for relapse
prevention in these groups. On the other hand, we have
no reason to believe that including individuals younger
than 18 years and older than 65 years would have altered
the findings in terms of feasibility and acceptability.
NRT is used only on the advice of a health professional
in pregnancy, and further research is still needed to
demonstrate its effectiveness and safety as a relapse pre-
vention intervention in pregnant smokers.
Of those entered into the study, 32% (95% CI 24% to
42%) self-reported being abstinent at six month follow
up, but the design of the study was such that it is not
possible to determine the efficacy of the RPI treatments
provided. This is because no control group (i.e. one not
offered RPI) was included and, hence, one cannot be
certain about the numbers of extra smokers who
remained abstinent at six months because of the RPI.
Self-reported smoking status has been shown to correl-
ate well with biochemical measurements. Murray et al.
(2002) [15] compared biochemical measures with self-
report and found that the size of the differences suggests
that self-report bias does not appear to result in “ser-
iously misleading findings in a smoking cessation study”.
As the purposes of this feasibility study did not include
assessing effectiveness, we only used self-reported smok-
ing abstinence at six months.
The method of sampling for the qualitative study meant
that only individuals who could be contacted were
interviewed and only a few people who had relapsed tosmoking were included. This is a potential source of selec-
tion bias and it seems likely that individuals interviewed
may have been more motivated to quit and respond more
favourably to the RPI. We were therefore unable to ex-
plore comprehensively the views of participants who had
relapsed to smoking. However, the interviews were carried
out with a mix of socio-demographics broadly reflecting
those eligible for treatment.
The majority of interviews were conducted during the
course of relapse prevention, but a few were conducted
after relapse prevention treatment had ended. The inter-
view findings do not suggest that the timing of the inter-
views had any impact on the perceptions of interviewees
regarding relapse prevention.
Important emergent issues
This study demonstrates that with the support of the NHS
SSS staff, a RPI involving NRT can be added to existing
treatment protocols, and that around half of eligible
smokers are likely to request it. This contrasts with the
reported perception of likely low demand for RPIs that
has previously been articulated by some NHS SSS staff
[12], although these perceptions were largely based on the
variable experiences of providing non-evidence based,
largely non-pharmacological RPIs in the NHS SSS. The
acceptance rate of the RPI offered in this study, in contrast
to these negative views suggests that using extended
courses of NRT is acceptable to NHS SSS clients.
Clients accepting the RPI in this study appeared to
represent a relatively deprived group of smokers; around
40% were unemployed, sick or disabled or carers and a
further third were routine or manual workers. This may
be because Nottingham City is known to have high
levels of deprivation [16]. A prospective cohort study of
smoking cessation treatment in primary care found that
smokers were more likely to receive smoking cessation
treatment if they lived in deprived areas, and this may
be due to the likelihood that more affluent smokers
buy supplies of NRT over the counter [17]. The main
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tion treatment were that the clients were satisfied with
the eight weeks of NRT they had already been supplied
or that they were unable to attend the monthly follow
ups. Older clients and clients who paid for their pre-
scriptions were more likely to accept the offer of ex-
tended support. The former finding is not surprising as,
in previous studies, older smokers have been found to
be more motivated and more likely to quit smoking than
their younger counterparts [18]. It possibly also suggests
that RPIs may be more attractive to those who had been
smoking for longer. Even though the sample of recent
quitters appeared to represent quite a deprived group,
the finding that clients who paid for their prescriptions
were more likely to accept the offer of RPI may be be-
cause clients who paid for their prescriptions were more
motivated to quit as they were willing to invest in the
quitting process.
Nearly all those who participated in the study reported
that they found it easy to use the NRT products. This find-
ing is not surprising as the literature suggests that NRT
products are generally easy to use [19]. The side effects
reported were also similar to the established side effect
profile of NRT and were all mild and transient [20].
Interviewees recognized that to remain successfully
quit, multiple factors are involved including: self motiv-
ation, pharmacological help, support informally through
family and friends and formally through services such as
NHS SSS, factors which have been identified previously
[21]. Most of the clients interviewed reported having
several failed quit attempts before, had smoked for a
long duration and tried various pharmacological and
non-pharmacological methods previously. Overall clients
were satisfied with the RPI they received; they identified
that prolonged nicotine replacement and behavioural
support were both key to their remaining quit.
Conclusion
It is feasible to offer a relapse prevention intervention in
the form of an extended course of NRT to smokers
through an NHS SSS and nearly half of those offered
such a treatment are likely to accept it, with 41% using
extended NRT for up to three months. This study also
shows that abstinent quitters find extended courses of
NRT acceptable and easy to use and they are positive
about receiving extended NRT as well as extended be-
havioural support through NHS SSS. Future research
should investigate the effectiveness of NRT used as a re-
lapse prevention aid in routine healthcare settings.
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